Clinical Trial DRUG CMEK162AUS11
- Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 3 - MEK162 for Patients with RAS/RAF/MEK Activated Tumors Local
- Principal Investigator
- Young Chae
- Status: COMPLETED
- Study Type: Therapeutic, Treatment
- Protocol No:.DRUG CMEK162AUS11
- The purpose of this clinical trial is to study if MEK162 is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with a RAS/RAF/MEK activated pathway. This pathway is thought to play a role in tumor cell growth as well as in the growth of new blood vessels, which supply the tumor with nutrients and oxygen.
- MEK162 is a drug that is being developed for the potential treatment of different tumor types and/or blood malignancies. MEK162 is a new type of drug that works by slowing down an important pathway (RAS/RAF/MEK) inside the cell involved in the development of certain types of cancers. This pathway (RAS/RAF/MEK) is thought to play a role in cell growth as well as in the growth of new blood vessels, which supply the tumor with nutrients and oxygen.
Some of the eligibility criteria include:
- Study participants must have a confirmed diagnosis of a select solid tumor (except for pancreatic cancer, biliary cancer, colorectal cancer, low grade serous ovarian cancer, melanoma) or hematologic malignancy.
- Participants must have had at least one prior treatment for cancer and it has returned (recurred) or it has spread beyond the initial cancer location (the cancer is metastatic and/or is locally advanced).
- Participants must have cancer for which no standard therapy options are anticipated to result in a lasting remission.
- Participants must have a tumor with a mutation in RAF, RAS, NF1 or MEK. This is determined by genetic testing.
- Description of Treatment
- In this study, a complete dosing cycle is 28 days. In each cycle, participants will take MEK162 twice a day, by mouth. Participants may continue to receive study drug unless they and/or the study doctor decide to stop the study drug dosing.
- Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
- Breast: Female
- Breast: Male
- Endocrine: Thyroid
- Endocrine: Other endocrine system
- Gastrointestinal: Anus
- Gastrointestinal: Esophagus
- Gastrointestinal: Stomach
- Gastrointestinal: Liver
- Gastrointestinal: Small intestine
- Gastrointestinal: Other digestive organ
- Genitourinary: Urinary bladder
- Genitourinary: Kidney
- Genitourinary: Other urinary
- Genitourinary: Prostate
- Genitourinary: Other male genital
- Ill-defined sites
- Leukemia: Lymphoid leukemia
- Leukemia: Myeloid leukemia
- Leukemia: Monocytic leukemia
- Leukemia: Leukemia, other
- Lung: Other respiratory, intrathoracic organs
- Lymphoma: Hodgkin's Disease
- Lymphoma: Mycosis Fungoides
- Lymphoma: Non-Hodgkin's Lymphoma
- Multiple Myeloma
- Skin: Kaposi's Sarcoma
- Skin: Other skin
- Soft Tissue
- Unknown, other
- Bones and joints
- Eye and orbit
- Gynecological: Cervix
- Gynecological: Corpus/Uterus
- Gynecological: Other female genital
- Head and neck: Buccal cavity/pharynx
- Head and neck: Esophagus
- Head and neck: Larynx
- Head and neck: Thyroid
Other Clinical Trials by Young Chae
- A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies
- A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination with Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung Cancer
- SHERLOC: A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
last updated: 17-Jan-17 09:06 AM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.